ReNeuron Group plc Directorate Change (0263S)
12 March 2021 - 6:00PM
UK Regulatory
TIDMRENE
RNS Number : 0263S
ReNeuron Group plc
12 March 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Directorate change
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces that Michael
Hunt, an executive director of the Company and its current Chief
Financial Officer, has yesterday resigned from the Company in order
to pursue other projects. Mr Hunt joined the Board in early 2001
and will remain with the Company until the end of May to facilitate
an orderly transition to his successor, when appointed. The Company
has initiated a search for Mr Hunt's replacement and a further
announcement will be made in due course.
Mr Hunt commented:
"After twenty years at the Company, and with the business now in
a much stronger financial position, it is the right time for me to
move on to new challenges. I am proud to have contributed to
ReNeuron's progression to be one of the leading players in the gene
and cell therapy sector, and I wish the Company and colleagues
every future success."
Olav Hellebø, Chief Executive Officer, commented:
"With tenures over the years as both CFO and CEO of the Company,
Michael has played a key role in the development of ReNeuron into
the exciting business that it is today. On behalf of ReNeuron, I
would like to thank Michael for his very significant contribution
to the Company and wish him well in his future endeavours."
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Michael Hunt, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Tim Sohal (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the brain. The Company also has the ability through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform to make any tissue cells of choice; in-house programmes
are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABIGDXSSBDGBB
(END) Dow Jones Newswires
March 12, 2021 02:00 ET (07:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024